NCT06371157

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Name: Clinical Trial NCT06371157
Creator: Akeso
Keywords: Hepatocellular Carcinoma, AK104, Phase 3, drug, clinical trial, China

A Phase III, Randomized, Double-blinded, Multicenter Study of Cadonilimab (AK104) + Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Akeso·Phase 3·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Hepatocellular Carcinoma
Drug/Device/Intervention: AK104
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Akeso
Location: Zhengzhou,Changsha,Nanjing,Taiyuan,Chengdu,Kunming,Hangzhou, China

Timeline & enrollment

Phase: Phase 3
Start date: Jul 02, 2024
End date: May 23, 2026
Enrollment: 469 participants

Primary outcome

Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Summary

A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma

ICD-10 classifications

Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06371157
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06371157 through Pure Global AI's free database. This Phase 3 trial is sponsored by Akeso and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 469 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.